Figure 6
Mutant embryonic hearts exhibit altered cardiac gene expression.
(A) qRT-PCR for the indicated gene expression in mutant embryonic hearts (RCLG/EIIa-Cre). The cropped gels are used in Fig. 6A and the full-length gel images are available in Supplementary Figure S28. The gels have been run under the same experimental conditions. (B,C) Western blot for the indicated proteins in E7.5-E14.5 mutant embryos and E11.5-E14.5 hearts (RCLG/EIIa-Cre). GAPDH was used as a control for the Western blot. Lane 1: Cre(E7.5); lane 2: RCLG/Cre(E7.5); lane 3: Cre(E8.5); lane 4: RCLG/Cre(E8.5); lane 5: Cre(E9.5); lane 6: RCLG/Cre(E9.5); lane 7: Cre(E10.5); lane 8: RCLG/Cre(E10.5); lane 9: Cre(E11.5); lane 10: RCLG/Cre(E11.5); lane 11: Cre(E12.5); lane 12: RCLG/Cre(E12.5); lane 13: Cre(E13.5); lane 14: RCLG/Cre (E13.5); lane 15: Cre(E14.5); lane 16: RCLG/Cre(E14.5). The cropped blots are used in Fig. 6B,C and the full-length gel images are available in Supplementary Figure S28. The blots have been run under the same experimental conditions. (D) Western blot analysis of the indicated proteins in E11.5 and E14.5 mutant embryonic hearts (RCLG/hUb-CreERT2). Lane 1: RCLG (E11.5); lane 2: RCLG/Cre(E11.5); lane 3: RCLG (E14.5); lane 4: RCLG/Cre(E14.5). The cropped blots are used in Fig. 6D and the full-length gel images are available in Supplementary Figure S28. The blots have been run under the same experimental conditions. (E) Immunohistochemical (IHC) analyses of Nkx2.5 and GATA4 expression in RCLG/EIIa-Cre embryonic hearts. ANF, atrial natriuretic peptide; α-SMA, α-smooth muscle actin; CNN1, calponin 1; MEF2C, Myocyte-specific enhancer factor 2C; MYCD, myocardin; MYH7B, myosin, heavy chain 7B; NCX1, cardiac sodium–calcium exchanger; SM22A, smooth muscle protein 22 alpha; SRF: serum response factor.
